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Executive Summary

Less than a century ago, cervical cancer was the number one cancer killer of women in
the U.S. With the advent of the Pap test in the 1940s, cervical cancer became a largely
preventable disease. Incidence and mortality rates for cervical cancer have fallen significantly
since that time, but the disease has yet to be eliminated. The American Cancer Society has
estimated that approximately 9,710 cases of invasive cervical cancer will be diagnosed and 3,700
women will die from cervical cancer in the U.S. in 2006. The Maine Cancer Registry reports that
58 women in Maine were diagnosed with invasive cervical cancer in 2003, and 15 women in
Maine died from the disease in that year.
While Maine has done relatively well with respect to cervical cancer prevention and early
detection efforts and while cervical cancer incidence and mortality rates in Maine are comparable
to national rates, the fact that this preventable disease exists at all is evidence that more can be
done. Recognizing the opportunity for the State to make significant progress toward complete
eradication of cervical cancer, the 12211 d Legislature established the Task Force to Study Cervical
Cancer Prevention, Detection and Education ("Task Force") by Resolves 2005, Chapter 121.
The Task Force was specifically created to examine the prevalence and incidence of cervical
cancer in Maine, to review preventive strategies and new technologies, to assess existing laws,
programs and services, and to develop a statewide cervical cancer prevention plan and strategies
for plan implementation and coordination.
The 16-member Task Force included one member of the Senate, two members of the
House of Representatives, eight members representing different medical organizations,
associations and specialties, one member representing the health insurance industry, one member
representing communications consultants, one member representing cervical cancer survivors
and two representatives of the Maine Department of Health and Human Services. The Task
Force convened on November 16, 2005 and held a total of 6 meetings to fulfill its duties. The
final meeting was held on October 17, 2006.
Summary of Task Force Recommendations
•

Increase public awareness and education regarding cervical cancer prevention, the
connection between the human papillomavirus and cervical cancer, and the
importance of screening. Strategies include a statewide public education campaign
on cervical cancer prevention and screening undertaken by the Maine Breast and
Cervical Health Program and school-based cervical cancer education initiatives
developed by the Maine Center for Disease Control and Prevention in coordination
with the Maine Department of Education.

•

Increase provider knowledge of cervical cancer screening guidelines and emerging
technologies in cervical cancer prevention and early detection. Strategies include
expanding continuing medical education offerings for medical professionals that

address clinical issues in cervical cancer prevention and detection and updating the
Maine Breast and Cervical Health Program's clinical guidelines for cervical cancer
screening.

•

Increase the number of Maine women who receive cervical cancer screening at
recommended intervals. Strategies include expanding access to screening for lowincome and uninsured women through the Maine Breast and Cervical Health Program
and the state family planning system, providing incentives for insured individuals to
get screened for cancer, and implementing systems to assist and support health care
providers in the delivery of cervical cancer screening consistent with clinical
guidelines.

•

Implement the recommendations of the United States Centers for Disease Control
and Prevention for the new hu1nan papillomavirus vaccine. Strategies include
increasing state funding to the Maine Immunization Program, monitoring the
vaccination rate and funding needs of that program and providing coverage for the
vaccine under the state's MaineCare (Medicaid) program.

•

Conduct public health research to improve and evaluate cervical cancer prevention
efforts. Strategies include examining cervical cancer incidence and prevention issues
among racial and ethnic minority populations in Maine, examining geographic
variation in cervical cancer within the State and the higher rates of cancer in Somerset
and Washington Counties, and, finally, conducting an evaluation of the state's
progress in cervical cancer prevention, detection and education in response to the
work of this Task Force.

ii

I.

INTRODUCTION

The Task Force to Study Cervical Cancer Prevention, Detection and Education was
established in the First Regular Session of the 122nd Legislature by Resolves 2005, Chapter 121. 1
The Task Force was created to examine the prevalence and incidence of cervical cancer in
Maine, to review preventive strategies and new technologies, to assess existing laws, programs
and services, and to develop a statewide cervical cancer prevention plan and strategies for plan
implementation and coordination. Specifically, the Task Force was charged with the following
six duties:
1. Review statistical and qualitative data on the prevalence and incidence of cervical cancer
in Maine;
2. Review preventive strategies and new technologies, including newly introduced vaccines
and their effectiveness in preventing and controlling the risk of cervical cancer, as well as
their relative costs;
3. Identify and examine the strengths and limitations of existing laws, regulations, programs
and services regarding coverage and awareness of cervical cancer;
4. Consider reports and testimony from individuals, local health depatiments, communitybased organizations, voluntary health organizations and other public and private
organizations statewide to learn more about their contributions to cervical cancer
diagnosis, prevention and treatment and their ideas for improving prevention, diagnosis
and treatment in Maine;
5. Develop, in consultation with the Department of Health and Human Services, a statewide
comprehensive cervical cancer prevention plan and strategies for plan implementation
and for promoting the plan and awareness of the causes, risk factors, prevention, early
detection and treatment of cervical cancer to the general public, state and local elected
officials and various public and private organizations, associations, businesses, industries
and agencies; and
6. Recommend strategies for coordination and communication among state and local
agencies and organizations regarding their involvement in achieving the aims of the
cervical cancer prevention plan.
The 16-member Task Force included one member of the Senate, two members of the
House of Representatives, eight members representing different medical organizations,
associations and specialties, one member representing the health insurance industry, one member
representing communications consultants, one member representing cervical cancer survivors
and two representatives of the Maine Department of Health and Human Services (DHHS). 2
1

Resolves 2005, Chapter 121 is provided in Appendix A.
The Task Force Membership list is provided in Appendix B. The position representing the Maine Osteopathic
Association has been vacant in 2006.
2
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Appointments to the Task Force were completed on October 19, 2005, and the Task
Force convened for its first meeting on November 16, 2005. At the first meeting, members
discussed the motivation for the study and identified the following justifications for undertaking
this work:
•

While Maine is doing relatively well in the areas of cervical cancer prevention,
detection and education, there is an opportunity for the State to further reduce the
rate of cervical cancer given the current technology and to move toward complete
eradication of cervical cancer with the development and introduction of new
technology, and

•

There are gaps in the current system of cervical cancer prevention, detection and
education in the State that need to be addressed.

To fulfill its duties, the Task Force held a total of 6 meetings between November 2005
and October 2006. 3 The Task Force submitted an initial report to the Joint Standing Committee
on Health and Human Services and the Governor in December 2005. The present report is the
final report of the Task Force. Pursuant to Resolves 2005, chapter 121, the joint standing
committee of the Legislature having jurisdiction over health and human services matters in the
First Regular Session of the 123 rd Legislature is authorized to report out legislation on cervical
cancer prevention, detection and education. 4

3

Meeting dates were: November 16, 2005; December 20, 2005; July 18, 2006; August 24, 2006; September 26,
2006; and October 17, 2006. Agendas for the Task Force meetings are provided in Appendix C. In accordance with
the authorizing legislation, the Task Force did not meeting during the 2006 Legislative session.
4
Draft legislation to implement the recommendations of the Task Force is provided in Appendix D.
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II.

CERVICAL CANCER INCIDENCE

Less than a century ago, cervical cancer was the number one cancer killer of women in
the U.S. 5 With the advent of the Pap test in the 1940s, cervical cancer became a largely
preventable disease. Incidence and mortality rates for cervical cancer have fallen significantly
since that time, but the disease has yet to be eliminated. The American Cancer Society has
estimated that approximately 9,710 cases of invasive cervical cancer will be diagnosed and 3,700
women will die from cervical cancer in the U.S. in 2006. 6
Cervical cancer incidence rates and mortality rates for Maine are similar to those for the
U.S. white population, particularly in recent years (see Figure 1 and Figure 2). 7 In 2003, the
approximately 8 per 100,000 women in Maine (58 women statewide) were diagnosed with
invasive cervical cancer, and 1.8 per 100,000 women in Maine died from the disease (15 deaths
statewide).

Figure 1 -Age-Adjusted Cervical Cancer Incidence Rates, 1990-2003
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5

"Cervical Cancer Prevention and HPV DNA Test," Health & Sexuality 19(1) 2005.
American Cancer Society, "Detailed Guide: Cervical Cancer," Revised August 2006,
http:/ /www.cancer.org/docroot/cri/cri_2_ 3x.asp?dt=8
7
The difference between cervical cancer incidence and mortality rates for Maine and U.S. whites are not statistically
significant. The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) collects cancer
information from 13 population based registries representing approximately 14% of the U.S. Population; because the
Maine population is 98% white, the Maine Cancer Registry uses the SEER U.S. white population data as a national
companson.
6
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Figure 2 -Age-Adjusted Cervical Cancer Mortality Rates, 1990-2003
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The incidence of invasive cervical cancer increases dramatically among women in their
mid-20s and early 30s (see Figure 3). This is consistent with the scientific evidence that cervical
cancer develops over a relatively long period of time following exposure to HPV (typically 10-15
years ifHPV or precancerous cells are not detected or treated). The incidence of invasive
cervical cancer among Maine women peaks for women ages 40-44 years and again for women
ages 70-7 4 years. This data suggests that targeting prevention efforts toward Maine girls and
young women would prove effective in decreasing cervical cancer incidence in the future. The
data also provide an important reminder that women over 60 years of age should not be neglected
in prevention and early detection efforts.
Figure 3- Age-Specific Cervical Cancer Incidence Rates, 1995-2003
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Within Maine, the highest rates of invasive cervical cancer are found in two
geographically separate areas: Somerset County in western Maine and Washington County in
eastern Maine (see Table 1). The age-adjusted incidence rates in these two counties are
significantly higher than the statewide rate. While the differences are not statistically significant,
lower rates of invasive cervical cancer are observed in southern and mid-coast counties,
including Cu1nberland, York, Sagadahoc and Knox counties.
Table 1 -Age-Adjusted Cervical Cancer Incidence Rates by Maine County, 1995-2003

County

9-Year
Count

Waldo

43
33
82
12
26
50
13
15
33
75
6
9
38
21

Washington

26

York

59

Androscoggin
Aroostook
Cumberland
Franklin
Hancock
Kennebec
Knox
Lincoln
Oxford
Penobscot
Piscataquis
Sagadahoc

Somerset

Maine
542
Source: Maine Cancer Registry.

Age
Adjusted
Rate per
100,000

8.7
9.0
6.2
8.6
10.2
8.6
6.0
9.0
11.9
10.7
7.2
5.5
15.6
11.4
15.0
6.4
8.6

Although racial and ethnic minority populations in Maine are presently too small to allow
for statistical analysis of racial and ethnic differences in cervical cancer within the state (and
guarantee the confidentiality of individuals), these populations are growing and such analysis will
likely be possible in the future. National data provide clear evidence of variation in cervical
cancer incidence by race and ethnicity. In 2002, the incidence rate per 100,000 was 8.2 among
white women in the U.S., 12.4 among Black women and 13.1 among Hispanic women. 8
Historically, Vietnamese American women have had the highest rates of cervical cancer, at
approximately five times the national rate (43 per 100,000 women during the period 19881992).9

8

National Cancer Institute, State Cancer Profiles, 2002, http://statecancerprofiles.cancer.gov
President's Advisory Commission on Asian Americans and Pacific Islanders, "Asian Americans and Pacific
Islanders Addressing Health Disparities: Opportunities for Building a Healthy America," 2003,
http://www.aapi.gov/Commission_Final_Health_Report.pdf
9
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Ill.

PREVENTION STRATEGIES AND NEW TECHNOLOGIES

A.

Cervical Cancer Screening

Cervical cancer is a highly preventable disease through regular screening. The
cornerstone of prevention for the last 60 years has been the Pap test. Developed by Dr. George
Papanicolaou, the Pap test is credited for producing a greater than 70% drop in the death rate
from cervical cancer since its introduction. 10 In 2004, nearly 89o/o of Maine women reported
having had a Pap test within the last three years, 3 percentage points higher than the national
median of 86o/o. 11 In addition to the Pap test, human papillomavirus (HPV) testing technology
has recently emerged as an additional tool for cervical cancer screening.
1. Pap Testing

The Pap test is used to detect abnormal changes in cervical cells that may lead to the
development of cervical cancer. Today, there are two key Pap test technologies: (1) the
conventional Pap smear, which involves "smearing" cervical cells onto a glass slide, and (2) the
newer thin-layer liquid-based Pap test approved by the FDA in 1996, which involves placing a
sample of cervical cells in liquid. 12 The newer liquid-based technology has proven to have
several advantages over the conventional Pap, including: higher quality sample; greater
effectiveness in detecting low-grade and high-grade intraepitheliallesions; and the ability to
conduct follow-up HPV testing without requiring the patient to return for another procedure.
Given these advantages, health care providers are increasingly choosing to use the liquid-based
Pap test over of the conventional Pap test. It is important to note that the liquid-based test is
more expensive, because of the associated laboratory work. 13
The state of Maine requires coverage for Pap tests through both law and program
regulations. In the case of private health insurance, state law requires that all group health
insurance policies and health maintenance organization (HMO) contracts cover "screening Pap
tests recommended by a physician." 14 Under the state Medicaid program, MaineCare, the Pap
test procedure and associated laboratory services are covered, except that laboratory services are
not covered for women in program's the "non-categorical" eligibility category (non-disabled,
childless adults). 15 Under the Maine Breast and Cervical Health Program, Pap tests are covered
for participating women (see section IV of this report for details on this program).

10

"Cervical Cancer Prevention and HPV DNA Testing," Health & Sexuality 10(1) 2005
U.S. CDC, Behavioral Risk Factor Surveillance System (BRFSS), http://apps.nccd.cdc.gov/brfss/
12
"Human Papilloma Virus Testing in Cervical Cancer Prevention," Medscape,
http://www.medscape.com/viewarticle/467126_6
13
The two largest independent laboratories serving Maine currently charge $37.10-$42.00 for the liquid-based test
and $22.80-$25.00 for the conventional Pap. Source: Maine DHHS.
14
24-A MRSA §§2837 and 4242.
15
See MaineCare Benefits Manual sections on Physician Services (Chapters II and III, Section 90), Family Planning
Agency Services (Chapters II and III, Section 30), and Laboratory Services (Chapters II and III, Section 55). See
also Non-categorical Adults List of Covered Services (Chapter I, Appendix 3).
11

6 • Cervical Cancer Prevention, Detection and Education

2. HPV Testing
HPV testing is increasingly being used to augment Pap testing in the diagnosis of cervical
cancer. The HC2 High-Risk HPV DNA test manufactured by Digene Corporation (HPV test)
was first approved by the U.S. Food and Drug Administration (FDA) in 2000 for use in the
evaluation of abnormal Pap tests results. 16 At that time, the test was specifically indicated for use
following an abnormal Pap to determine whether to proceed to a colposcopy, a procedure in
which the outer portion of the cervix is examined using an instrument called a colposcope to
magnify and illuminate the area. In 2003, the FDA approved expanded use of the HPV test in
women over 30 years. Specifically, it approved the use of this test in primary screening of
women over 30 years for cervical cancer, when used in conjunction with the Pap test. 17 Used in
this way, the HPV test presents the opportunity to extend the cervical cancer screening intervals
for women over 30 years with negative Pap tests and negative HPV tests.

3. Screening Guidelines
Cervical cancer screening guidelines are provided by three national medical
organizations: (1) the American Cancer Society (ACS), (2) the U.S. Preventive Services Task
Force 18 (USPSTF), and (3) the American College of Obstetricians and Gynecologists (ACOG).
As shown in Table 2, the recommended starting point for screening is similar across the three
guidelines, but the guidelines different somewhat regarding the time between screening tests,
screening interval, and when to stop screening. While annual screening is common practice
today, it is important to note that the guidelines advise less frequent screening in specific
situations.

4. Cervical Cancer Screening Failure
Given the existing screening technology, it is estimated that 95% of cervical cancer could
be prevented under perfect conditions. 19 In reality, 30o/o of cervical cancer cases are not
prevented as a result of imperfections, or failures, in the screening system. Screening failures can
be divided into two major types:
1. Insufficient screening. Approximately 65-70% of screening failures are the result of
women not being screened. This includes women who have never been screened and
women who are screened less frequently than is recommended, and
2. False negative screening. Approximately 30-35% of screening failures are the result of
"false negative" screening, in which a woman is screened but still develops cervical
cancer.
16

U.S. Food and Drug Administration, http://www.fda.gov/cdrh!pdf/P890064s009b.pdf
U.S. Food and Drug Administration, http://www.fda.gov/cdrh!pdf/p890064s009a.pdf
18
The USPSTF, sponsored by the U.S. DHHS Agency for Healthcare Research and Quality (AHRQ), is an
independent panel of experts in primary care and prevention that reviews the scientific evidence of effectiveness and
develops recommendations for clinical preventive services.
19
Presentation of Dr. Michael Jones to the Task Force on December 20, 2005.
17
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Table 2 - Cervical Cancer Screening Guidelines 20

Recommendation
When to Start Screening

Screening Interval
If conventional Pap smear test

American Cancer
Society
(Nov. 2002)
Approximately 3
years after onset of
vaginal intercourse,
but no later than age
21

U.S. Preventive
Services Task Force
(Jan. 2003)
Within 3 years of
onset of sexual
activity or age 21,
whichever comes first

American College of
Obstetricians and
Gynecologists
(Aug. 2003)
Approximately 3
years after onset of
sexual intercourse, but
no later than age 21

a) Annually
b) Every 2-3 years for
women ?::30 yrs with 3
negative cytology
tests

At least every 3 years

a) Annually
b) Every 2-3 years for
women ?::30 yrs with 3
negative cytology
tests

If liquid-based cytology test

a) Every 2 years
b) Every 2-3 years for
women ?::30 yrs with 3
negative cytology
tests

Insufficient evidence

a) Annually
b) Every 2-3 years for
women ?::30 yrs with 3
negative cytology
tests

If HPV testing used

Every 3 years if HPV
negative, cytology
negative
Women?:: 70 yrs with
?:: 3 recent,
consecutive negative
tests and no abnormal
tests in prior 10 years

Insufficient evidence

Every 3 years if HPV
negative, cytology
negative
Inconclusive evidence
to establish upper age
limit

When to Stop Screening

B.

Women > 65 yrs with
negative tests, who
are not otherwise at
high risk for cervical
cancer

Cervical Cancer Vaccines

The newest technology in the fight against cervical cancer is the HPV vaccine. Infection
by HPV is well-established as the most important risk factor for cervical cancer, and research has
shown the presence of HPV in over 93% of cervical cancers. 21 HPV is a very common infection.
The U.S. Centers for Disease Control and Prevention (CDC) has estimated that 20 million people
in U.S. were infected with HPV in 2005 and 80% of women have been infected by HPV by age
50. 22 Most HPV infections are transient and resolve on their own without medical intervention
and do not develop into cervical cancer. 23 However, when HPV does not go away on its own,
20

"Summary Tables of Cervical Cancer Screening Guidelines and Recommendations for New Technologies," U.S.
Department of Health and Human Services (DHHS), Centers for Disease Control and Prevention (CDC),
http://www.cdc.gov/std/hpv/ScreeningTables.pdf
21
National Cancer Institute. "Cervical Cancer: Backgrounder,"
http://rex.nci. nih. gov /massmedia/backgrounders/cervical.htrnl
22
"CDC's Advisory Committee Recommends Human Papillomavirus Virus Vaccination," U.S. CDC,
http://www.cdc.gov/od/oc/media/pressrel/r060629.htm
23
Presentation of Dr. Michael Jones to the Task Force on December 20, 2005.
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certain types of the virus can develop into cervical cancer. There are more than 100 types of
HPV, but only certain types have been linked to the development of cervical cancer, including
HPV 16 which is estimated to account for 50% of cervical cancer, and HPV 18, 31 and 45, which
together are estimated to account for 30o/o of cervical cancer. 24
Given the strong link between HPV and cervical cancer, vaccines that protect against
HPV have the potential to play an important role in preventing cervical cancer, particularly
among women who are not getting screened at the recommended intervals. It is important to
note that even once vaccines are available, screening will remain critical to cervical cancer
prevention for a number of reasons, including the fact that the vaccines do not protect against all
strains of HPV that cause cervical cancer, the vaccines do not treat existing HPV infection, and
there are many women today who will not receive the vaccines. It is also important to recognize
that there will be a significant lag period between the introduction of HPV vaccines and a
reduction in cervical cancer incidence and mortality rates, due to the latency associated with this
cancer. Additionally, acceptance of the vaccines among health care providers and consumers is
an important practical challenge that will need to be addressed to fully realize the potential of
these vaccines.

1. Gardasil
On June 8, 2006, the FDA approved Gardasil, for use in females ages 9-26 for the
"prevention of cervical cancer and other diseases caused by HPV." 25 ' 26 Manufactured by Merck
and Co, Inc., Gardasil is the first vaccine approved by the FDA for cervical cancer prevention.
Gardasil targets four types ofHPV: 6, 11, 16 and 18. HPV types 16 and 18 are leading causes of
cervical cancer, accounting for 70% of all cervical cancer cases. 27
On the basis of Merck's clinical trials, involving 21,000 women worldwide, the FDA
concluded that:
Gardasil was nearly 100 percent effective in preventing precancerous cervical lesions,
precancerous vaginal and vulvar lesions, and genital warts caused by infection with the
HPV types against which the vaccine is directed. While the study period was not long
enough for cervical cancer to develop, the prevention of these cervical precancerous
lesions is believed highly likely to result in the prevention of those cancers. 28

24

Shah, Keerti V. (1997). "Human Papillomaviruses and Anogenital Cancers." The New England Journal of
Medicine, 337(19) 1386-1388.
25
"FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human
Papillornavirus," FDA, http://www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html
26
Merck is currently conducting clinical trials with women aged 27-45 years and with men. Dr. Liana Clark, Merck,
presentation to the Task Force, August 24, 2006.
27
Merck is developing a vaccine that will cover 8 types of HPV; the company hopes to have that drug approved by
2010. Dr. Liana Clark, Merck, presentation to the Task Force, August 24, 2006.
28
"FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human
Papillomavirus," FDA, http://www.fda.gov/bbs/topics/NEWS/2006/NEWO 13 85 .html
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Following the FDA's approval ofGardasil on June 8, the CDC's Advisory Committee on
Immunization Practices (ACIP) voted on June 29, 2006, to recommend routine vaccination with
three doses of Gardasil for all girls ages 11-12 years, as well as "catch-up" vaccination of girls
and women ages 13-26 years who have not received the vaccine or completed the 3-injection
series. Routine vaccination at ages 11-12 years is designed to catch most girls prior to any
exposure to HPV, so that the vaccine can have its maximal effect. These recommendations were
posted by the CDC as "Provisional Recommendations" in August 2006 and final publication of
the recommendations is expected in November 2006. 29

2. Cervarix
GlaxoSmithKline (GSK) is currently seeking FDA approval for its HPV vaccine,
Cervarix. Cervarix is a bivalent vaccine that targets HPV types 16 and 18. Phase III clinical
trials of Cervarix are currently in progress, and GSK submitted its Biologics License Application
(BLA) in 2006. Like Gardasil, Cervarix has been shown to be highly effective in preventing
persistent HPV infection and HPV type-specific associated lesions. 30

29

"ACIP Provisional Recommendations for the Use ofQuadrivalent HPV Vaccine," U.S. CDC,
http://www.cdc.gov/Nip/recs/provisional_recs/hpv.pdf
30
Diane M. Harper, MD, MPH, MS. Presentation, Conference on "The Status of Cervical Cancer Vaccine
Research", Women's Policy, Inc., Washington, DC, December 6, 2005.
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IV.

EXISTING PROGRAMS AND SERVICES

The Task Force reviewed and examined the strengths and limitations of current programs
and services in the State that contribute to cervical cancer prevention, detection and education.
Through reports, presentations and discussions, the Task Force developed the following
inventory of key state agencies and organizations involved in various aspects of cervical cancer.

A.

Maine Breast and Cervical Health Program

The Maine Breast and Cervical Health Program (MBCHP) provides free cervical cancer
(and breast cancer) screening and related diagnostic services for low-income and uninsured
women in the state. This program operates within Maine DHHS under authorization and funding
from the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) of the U.S.
CDC. The NBCCEDP, which was established by Congress under the Breast and Cervical Cancer
Mortality Prevention Act of 1990, is the first and only national cancer screening program. Maine
is one of over 60 states and tribal organizations that have received funding from the CDC to
implement a comprehensive breast and cervical cancer health program. Key features of the
program are as follows:
•

Funding. MBCHP currently receives nearly $1.8 million in annual funding from
the U.S. CDC. These federal funds are supplemented with approximately
$370,000 in state General Fund dollars.

•

Eligibility. Eligibility for MBCHP is based on age, income, insurance status and
residence. Under current MBCHP rules, women who are 40 years and older, have
income at or below 250% of the federal poverty level, are uninsured or
underinsured, and reside in Maine or New Hampshire are eligible. 31

•

Enrollment. Since its inception, MBCHP has enrolled over 16,700 women,
provided 25,820 Pap tests and diagnosed 61 cases of cervical cancer, including 5
cases of invasive cervical cancer and 56 cases of carcinoma in situ of the cervix. 32
Current program enrollment is over 5,300 women, with approximately one-third
age 40-49 years and the remaining two-thirds age 50 years and older. 33
Enrollment rates vary from 43% of eligible women in Washington County down
to 7% of eligible women in Cumberland County. 34

•

Covered clinical services. For enrollees, the MBCHP provides an annual exam,
including a clinical breast exam, pelvic exam and a Pap test. An HPV test is

31

The U.S. CDC gives the option of eligibility starting at age 18; due to the limited funding for MBCHP and the
availability of family planning services for younger women, Maine decided to begin eligibility at age 40.
32
Carcinoma in situ is noninvasive; cancer cells are in the first layer of cells lining the cervix only and have not
invaded the deeper tissues. Source: National Cancer Institute.
33
As of October 6, 2006, MBCHP reports 5,329 women enrolled.
34
Source: Maine Department of Health and Human Services, Maine Breast and Cervical Health Program.
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covered following an abnormal result on a Pap test. Cancer treatment is not
covered by MBCHP but, in most cases, is covered by MaineCare pursuant to the
federal Breast and Cervical Cancer Prevention and Treatment Act of 2000.

•

B.

Service delivery system and outreach. MBCHP funds more than 300 sites to
provide clinical and educational services. These include: primary care provider
sites which provide clinical exams and pap tests; other health care professionals
who provide diagnostic services on referral; laboratory facilities that provide
cytology and pathology services; and six community partnerships that provide
public education and other support services in six counties. In 2005, the MBCHP
distributed 70,000 brochures and 1,900 posters to 441 sites across the state.

MaineCare and the Treatment Act

Since 2001, Maine has provided Medicaid (MaineCare) coverage for cancer treatment to
women diagnosed with cervical cancer, or breast cancer, under the MBCHP. This coverage was
established in accordance with the federal Breast and Cervical Cancer Prevention and Treatment
Act of2000 (the Treatment Act), through Maine Public Law 2001, chapter 439, Part TT, which
required DHHS to amend its rules to provide full MaineCare coverage to eligible women
diagnosed with breast or cervical cancer by the MBCHP. Approximately two years following
this rule change, Maine applied for and received federal approval for a less restrictive option
allowed under the federal Treatment Act, under which the state provides MaineCare coverage to
eligible women who are not enrolled in MBCHP but who: (a) meet MBCHP eligibility
requirements and (b) are screened or diagnosed at a participating MBCHP site. 35
To be eligible for MaineCare under the Treatment Act provisions, a woman must be
under age 65, not covered by credible health insurance, and have income less than 250% of the
federal poverty level. 36 MaineCare coverage under these rules is continuous for at least one year
as long as the woman is receiving cancer treatment. Since 2001, a total of 103 women with
cervical cancer or pre-cancer have enrolled in MaineCare under these rules.

C.

Maine Cancer Registry

The Maine Cancer Registry (MCR) has an important role in cervical cancer prevention as
the source of statewide data and expertise regarding cancer incidence. The MCR was established
by the Legislature in 1983 to provide a population-based cancer surveillance system for the
state. 37 The registry, which operates within the Maine CDC, DHHS, receives federal funding
35

This change was motivated by LD 143, Resolve, to Improve Access to Breast and Cervical Cancer Treatment,
which was proposed in the 121 st legislature. Ultimately, LD 143 was not enacted after the department agreed to
make the changes without legislation.
36
Specifically the individual must have no "credible coverage" as defined in Section 2701(a) of the federal Public
Health Service Act.
37
22 MRSA § 1404.
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under the National Program of Cancer Registries, a program of the U.S. CDC. These federal
dollars are matched with state funds, at a ratio of $3 federal to $1 state.
The MCR collects patient demographic, diagnosis and initial treatment data on cases of
cancer diagnosed in Maine. With respect to cervical cancer, the MCR collects data on cases of
invasive cervical cancer (cervical cancer that has invaded surrounding tissues); it does not collect
data on cervical carcinoma in situ (noninvasive). 38 The data is collected by MCR comes from
hospitals, health care facilities, physicians and other health care providers who diagnose or treat
cancer patients. The MCR law requires health care providers and facilities to report new cases of
cancer within six months of diagnosis. 39 The MCR uses the data it collects to monitor and
evaluate cancer trends in Maine, to identify areas in need of public health interventions and to
improve cancer prevention, treatment and control. The MCR publishes an annual cancer
incidence report that includes statistical comparisons between Maine and the nation for various
cancer types, including invasive cervical cancer.

D.

Maine Immunization Program

With the recent introduction of the HPV vaccine, the Maine Immunization Program
(MIP) within DHHS is positioned to become an important player in the state's cervical cancer
prevention efforts. Under its "universal purchase policy," Maine purchases and distributes to
public and private health care providers statewide all of the CDC-recommended vaccines for all
children aged 0 to 18 years, as well as influenza, pneumococcal and first dose measles, mumps,
rubella for adults. Currently, the MIP distributes approximately 300,000 doses of vaccine
annually to over 700 health care providers in the state. 40 In addition to its vaccine purchase and
distribution functions, the MIP also measures immunization rates, provides education and
information regarding immunization issues, monitors vaccine usage and maintains an electronic
immunization registry.
Funding of the MIP emerged as an important issue of concern to the Task Force. The MIP
currently receives funding to purchase vaccine from the following sources:

•

38

39
40

Vaccines for Children (VFC). Vaccines for Children is a federal entitlement program
that provides vaccines recommended by the U.S. CDC's Advisory Council on
Immunization Practices (ACIP) at no cost for children aged 0-18 years in the following
categories: Medicaid-eligible; uninsured; insured but insurance does not cover childhood
immunizations (these children must go to a Federally Qualified Health Clinic or Rural
Health Clinic); and Native American or Alaskan Native. In 2005, the U.S. CDC awarded
$3.2 million in VFC-purchased vaccines for Maine children who qualify for VFC. On

The MCR also does not collect data on basal cell and squamous cell carcinoma of the skin.
22 MRSA § 1402.
Source: Maine Immunization Program, http://www.maine.gov/dhhs/bohlmip/vaccine_related.html
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November 1, 2006, Merck announced that the U.S. CDC added Gardasil to the VFC
contract. 41
•

Section 317 Grant Program. The Section 317 program is a federal grant program that
provides funding for vaccines for underinsured children not covered under VFC, and for
adults. This is a discretionary annual appropriation at the federal level. In 2005, the U.S.
CDC awarded $2.9 million in Section 317 funding to Maine.

•

Private Health Insurance Plans. Under an oral agreement between the State and six
HMOs under the umbrella of the Maine Association of Health Plans, six HMOs make an
annual contribution to support the state's purchase of vaccine for children. 42 In 2005, the
six HMOs contributed $700,000 to the state for vaccine purchase for children.

•

Fund for a Healthy Maine (FHM). Under a recent Maine law, certain FHM (tobacco
settlement) dollars have been allocated specifically for the purchase of influenza vaccine
for adults. 43 In 2005, $1.2 million in FHM dollars were made available for this purpose.

There is currently no General Fund support for the purchase and distribution of vaccines. The
lack of General Fund support for this program poses a significant challenge to the MIP in its
efforts to carry out the state's universal purchase policy. This challenge increases with each year
as new vaccines are recommended, the prices for vaccines increase and federal appropriations for
the Section 317 grant program fail to keep up with these recommendations. 44 Even before the
addition of the new HPV vaccine, the MIP has estimated that to cover 80% of Maine children
with the CDC recommended vaccines, the program needs an additional $2.5 million per year for
vaccines for children aged 0-10 years, and an additional $1.5 million for vaccines for children
aged 11-18 years. 45

E.

Maine Cancer Consortium

The Maine Cancer Consortium was established in 1999 to develop and implement a state
cancer control plan. Today, the consortium is a statewide partnership including 300 individuals
representing over 130 public and private organizations. The Consortium relies on its members to
seek and provide funding which comes from variety of public and private sources. Membership
in the Consortium is open to anyone interested in its mission, which is "to reduce the burden of
cancer in Maine by working collaboratively to optimize quality of life by improving access to
care, prevention, early detection, treatment, rehabilitation, survivorship, palliation and end of life

41

"Product News: Merck's Cervical Cancer Vaccine, Gardasil®, Added to the CDC Vaccines for Children
Contract," Merck, http://www.merck.com/newsroom/press _releases/product/2006 _11 0 1.html
42
The amount of the contribution is based on the HMO's self-reported number of children within specific age
groups.
43
PL 2003, c. 451, Pt RR.
44
Cochi, Stephen L. MD, MPH. "Vaccine Financing from the National Immunization Program's Perspective,"
National Immunization Program, U.S. CDC, June 2004.
45
Source: Maine Immunization Program, data provided to the Task Force, September 2006.
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care."46 The focus of the Consortium's work continues to be the development and
implementation of the state cancer plan. In May 2006, the Consortium released the Maine
Cancer Plan 2006-2010. The plan includes a specific section on cervical cancer, as well as a
47
section on sexual health that addresses HPV prevention.

F.

Maine Comprehensive Cancer Control Program

The Maine Comprehensive Cancer Control Program, or Comp Cancer, was established by
the Legislature in 2003 to coordinate Maine's cancer control efforts, including prevention,
research and treatment activities. 48 Comp Cancer is a participating program of the U.S. CDC
National Comprehensive Cancer Control Program, and is entirely supported by federal funds at
this time. Current objectives of Comp Cancer include: expanding collaborative efforts in place
through the Maine Cancer Consortium; increasing use of the Maine Cancer Plan; providing
technical assistance to state and local organizations; conducting public awareness projects; and
evaluating implementation of the Maine Cancer Plan. 49 In the area of screening, Comp Cancer
has launched a public awareness campaign for colo rectal cancer screening. 50

G.

Family Planning Services

The state family planning system has an important clinical and educational role in
cervical cancer prevention. At the center of the system is the Family Planning Association of
Maine (FP A), which was founded in 1970. The FP A is the Maine grantee for federal family
planning funding under Title X of the Public Health Services Act. As the Title X grantee for the
state, the FP A provides funding and assistance to a network of 11 delegate agencies that operate
a network of 45 family planning clinic sites statewide, which provide comprehensive
reproductive health services, including cervical cancer screening and related tests. In 2005,
Maine family planning clinics served over 30,000 clients. More than half of these clients (52o/o)
had income at or below the federal poverty level and just under half of the clients were 18 to 24
years of age (46%). 51 In addition to clinical services, the FPA also provides outreach and
education, including family life education programs, and works to advance the cause of
reproductive freedom.
The FPA is a private non-profit organization. In addition to federal funds, FPA receives
state funds, including approximately $1.3 million from the General Fund to support clinical
services and family life education and $0.4 million from the Fund for Healthy Maine to conduct
outreach to high-risk populations. Additional revenue sources include fees, reimbursement by
third-party insurance, private fund-raising, grants from private foundations, and investments.
46

Maine Cancer Consortium, http://www.mainecancerconsortium.org/welcome.html
These sections of the Maine Cancer Plan are provided in Appendix E.
48
PL 2003, c. 215; 22 MRSA §1407.
49
Maine Comprehensive Cancer Control Program, http://www.maine.gov/dhhs/bohlccc/index.htrn
50
Screen Me materials can be viewed on line at http://www.maine.gov/dhhs/bohlccc/screenme.htrn
51
Presentation of Evelyn Kietlyka, Family Planning Association of Maine, to the Task Force on August 24, 2006.
47
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V.

CERVICAL CANCER PREVENTION PLAN- RECOMMENDATIONS

Based on its review and assessment of cervical cancer incidence, prevention technologies,
the current array of programs and resources available in the state and the recommendations of the
Maine Comprehensive Cancer Control Plan 2006-2010, the Task Force has developed its
recommendations for a plan of action to eliminate cervical cancer in Maine. The Task Force
recommendations, including specific actions and strategies, are organized around the following
objectives:
•

Increase public awareness and education regarding cervical cancer prevention, the
connection between HPV and cervical cancer, and the importance of screening;

•

Increase provider knowledge of cervical cancer screening guidelines and emerging
technologies in cervical cancer prevention and early detection;

•

Increase the number of Maine women who receive cervical cancer screening at
recommended intervals;

•

Implement the recommendations of the U.S. CDC for the new HPV vaccine; and

•

Conduct public health research to improve and evaluate cervical cancer prevention
efforts.

The Task Force recognizes that there are costs attached to each of its recommendations and
further recommends that the State appropriate and allocate the funds necessary to implement its
proposals, as outlined below.

A.

Public Awareness

Objective: Increase public awareness and education regarding cervical cancer prevention,
the connection between HPV and cervical cancer, and the importance of screening.
Recommended strategies:

1. Direct the Maine Breast and Cervical Health Program (MBCHP) to implement a
statewide public education campaign on cervical cancer prevention and screening, as
follows:
a. Develop and distribute printed informational materials to all sites that
currently receive MBCHP brochures, 52 plus additional locations statewide

52

In 2005, MBCHP brochures were distributed to 441 sites, including DHHS offices, hospitals, primary care
providers and mammography facilities.
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including libraries, shopping malls, grocery stores, hair salons, pharmacies and
health care facilities; offer these materials to faith-based organizations.
b. Coordinate specific educational outreach initiatives for racial and ethnic
minorities in the state, particularly in Portland, Lewiston, and Bangor, and
develop multi-lingual fact sheets and informational materials, as appropriate. 5 3
c. Collaborate with organizations representing senior citizens and retired persons
to ensure the public awareness campaign reaches women over 60 years.
d. Increase the broadcast of MBCHP public service announcements from the
current 4 months (January-April) to all 12 months of the year.
2. Direct the Maine CDC to implement school-based cervical cancer education
initiatives, as follows:
a. Develop printed educational materials appropriate for posting at middle and
secondary schools and universities, including multi-lingual versions as
appropriate. Partner with the Department of Education (DOE) and the
University of Maine System to coordinate the distribution and posting of
materials at public schools and universities. Include restrooms as a site for
posting these materials. Offer the materials to private schools and
universities.
b. Develop an educational pamphlet for 5th grade students regarding the
availability of the HPV vaccine. 54 Work with DOE health education staff,
school nurses and health coordinators to facilitate distribution of the pamphlet
in public schools. Provide copies of the pamphlet to all pediatricians and
family physicians licensed in the state. Offer the pamphlet to private schools.
c. Develop, in collaboration with DOE health education staff, a "speakers'
network" consisting of medical professionals willing to speak about cervical
cancer prevention in health education classes or other school forums.
d. Seek grant funding to implement an activity-based cervical cancer education
initiative in Maine schools. 55

53

Cancer Care Ontario (Canada) has a fact sheet "HPV and Cancer of the Cervix" in English and 14 other languages.
See for example: http://www.cancercare.on.ca/pdf/ocsp_somali_hpv.pdf (Somali)
http://www.cancercare. on. ca/pdf/FSHPVE. QXD. pdf (English)
54
Fifth grade was selected because the federal CDC recommendation is to begin vaccination at 11-12 years.
55
See for example, the "Make the Connection" campaign and bracelet activity recently conducted by the Cancer
Research and Prevention Foundation and Step Up Women's network, with support from Merck and Co.; see:
www .maketheconnection. org
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B.

Provider Knowledge

Objective: Increase provider knowledge of clinical guidelines for cervical cancer
screening and emerging technologies in cervical cancer prevention and early detection.
Recommended strategies:
1. Direct the Maine CDC to work with the Maine Medical Association's Committee on

Continuing Medical Education and Accreditation to increase continuing medical
education (CME) offerings regarding cervical cancer. Recommend that the content
of these offerings include, but not be limited to:
o

Current clinical guidelines for cervical cancer screening, including new
developments in screening and situations in which the guidelines
recommended screening less frequently than annually;

o

HPV vaccines, including status of vaccine development and U.S. CDC
recommendations; and

o

Emerging issues and technologies in prevention, detection and treatment of
cervical cancer.

Recommend that the expanded offerings include self-study options, such as on-line
CME programs. 56 Encourage the Maine Medical Association to conduct outreach
efforts to promote cervical cancer CME offerings and to inform providers of
insurance coverage for the HPV vaccine.
2. Direct MBCHP to review and update the program's clinical guidelines for cervical
cancer screening, taking into account the most recent guidelines published by the
American Cancer Society, the American College of Obstetricians and Gynecologists
and the U.S. Preventive Services Task Force. Direct MBCHP to offer a professional
education program on this subject after the review and update is complete.

C.

Screening

ObJective: Increase the number of Maine women who receive cervical cancer screening
at recommended intervals, with a primary focus on increased screening among women who are
screened less frequently than recommended, and a secondary focus on decreased screening
among women who are screened more frequently than recommended.

56

See for example, existing on-line courses designed by American Society of Colposcopy and Cervical Pathology
(ASCCP) in collaboration with American Social Health Association (ASHA),
http://www.asccp.org/edu/home_study.shtml
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Recommended strategies:
1. Implement the recommended "public awareness" and "provider knowledge" strategies
to increase understanding of the importance of screening for cervical cancer and the
recommended screening intervals.

2. Expand access to cervical cancer screening for low-inc01ne and underserved women
as follows:
a. Expand the MBCHP program to provide cervical cancer screening to women
under 40 years; the first priority must be to add women ages 35-39 years to the
program and target services to those women who have never been screened or
only rarely screened for cervical cancer. 57
b. Direct the MBCHP to collaborate with the Family Planning Association of
Maine (FP A) to develop ideas for outreach and coordination to increase
cervical cancer screening among women ineligible for MBCHP, particularly
women ages 18-35 years.
c. Direct the MBCHP to expand its "special screening day" program, at which
women who are newly enrolled in MBCHP receive their Pap tests and
1nmnmograms at a single site. 58 Direct MBCHP to consider new locations and
as well as additional days in existing locations as potential expansion
strategies.
d. Direct DHHS, Office ofMaineCare Services, in consultation with MBCHP
and FP A, to evaluate the possibility of applying for a federal Medicaid Family
Planning Waiver in order to extend coverage for cervical cancer screening to
more low-income women in Maine.
3. Direct the MBCHP in consultation with Maine Comprehensive Cancer Control

Program, the Maine State Employee Health Commission, the American Cancer
Society and private insurance companies and to explore options for encouraging
insured individuals to make and attend medical appointments for cancer screenings,
including cervical cancer. 59
4. Direct the Maine Quality Forum (MQF) to identify and assess the status of current

efforts and initiatives by health insurers and health care providers that may enhance
the delivery of cervical cancer screening and follow-up care, including but not limited
to:

57

Eligibility currently begins at 40 years.
Task Force member, Dr. James A. Raczek, representing the Academy of Family Physicians voted against this
recommendation.
59
Examples may include giving employees time off from work for cancer screening appointments.
58
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D.

o

Computer-based clinical improvement tools designed for health care providers
to track and manage patient care, including cervical cancer screening.

o

Provider incentives to conduct cervical cancer screening at recommended
intervals, including health care quality and performance measures.

HPV Vaccine
Objective: Implement recommendations of the U.S. CDC for the new HPV vaccine.
Recomnzended strategies:
1. Make funding for the HPV vaccine a high priority. Specifically, increase state
funding to the Maine Immunization Program (MIP), including a General Fund
appropriation. Require that a portion of the appropriation be designated for the HPV
vaccine, including purchase, distribution and associated operational costs.
2. Direct the MIP to report to the joint standing committee of the Legislature having
jurisdiction over health matters regarding program funding and vaccination rates,
including:
o

The overall program budget for the current year and previous two years,
including specific information regarding the HPV vaccine expenditures;

o

State and national immunization rates for childhood vaccines, including HPV;
and

o

An update on the funding gap, specifically the additional funds needed to
vaccinate 80% of Maine children with CDC recommended vaccines, including
HPV.

Require the MIP to submit an initial report no later than January 30, 2008, and a
follow-up report no later than January 30, 2010.
3. Direct DHHS to provide coverage under the state MaineCare (Medicaid) program for
the HPV vaccine consistent with U.S. CDC recommendations.
4. Integrate HPV vaccine information into "public awareness" and "provider
knowledge" strategies outlined above.
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E.

Further Research and Evaluation

Objective: Conduct public health research to improve and evaluate cervical cancer
prevention efforts.
Recommended strategies:
1. Direct the Office of Minority Health to work with the Maine Cancer Registry, the
Maine Comprehensive Cancer Control Program and the Office of Multicultural
Affairs to examine cervical cancer incidence and prevention issues among racial and
ethnic minority populations in Maine, including:
o

Available data on cervical cancer among racial and ethnic minorities;

o

Barriers to screening and treatment across different racial and ethnic
minorities; and

o

Best practices in education and outreach to racial and ethnic minorities.

2. Direct the Maine Cancer Registry and the Maine Breast and Cervical Health Program
to examine the geographic variation in cervical cancer rates within Maine, focusing
on the higher rates of cervical cancer in Washington County and Somerset County
and why the rates in these locations are higher than in other areas of the state. Direct
the MCR and MBCHP to collaborate with the American Cancer Society, community
organizations and health care providers to develop recommendations for reducing the
incidence of cervical cancer in these counties.
3. Direct the Maine CDC to monitor and evaluate the state's progress in cervical cancer
prevention, detection and education in response to the work of the Task Force.
Require the Maine CDC to review the status and outcome of each Task Force
recommendation and report its findings and recommendations, including any
legislation, to the joint standing committee of the Legislature having jurisdiction over
health services. Require an initial and final evaluation report as follows:

F.

o

Initial report no later than January 30, 2009, and

o

Final report no later than January 30, 2011.

Addendum

The following two recommendations were made after the final meeting of the Task Force
and were not endorsed by the group as a whole.
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1. Direct the Maine CDC to convene a stakeholder group in 2010 to evaluate the
progress of HPV vaccination in Maine and examine the potential costs and benefits of
adding the HPV vaccine to the immunizations required for school attendance.
Require the Maine CDC to report its findings and recommendations to the joint
standing committee of the Legislature having jurisdiction over health and human
services matters by January 15, 2011. 60
2. Target additional cervical cancer prevention, detection and education efforts to
Somerset and Washington Counties as follows: 61
a. Direct the MBCHP to conduct specific educational outreach initiatives for
women in Somerset and Washington Counties.
b. Direct the Maine CDC, working with the Maine Medical Association's
Committee on Continuing Medical Education, to target medical professionals
in Somerset and Washington Counties when expanding CME offerings
regarding cervical cancer (as described under "provider knowledge"
recommendations).
c. Prioritize Washington and Somerset Counties in efforts to increase cervical
cancer screening rates.

60

Task Force members, Rep. Lisa T. Marrache, Co-Chair of the Task Force, and Dr. Jonathan T. Fanburg,
representing the American Academy of Pediatrics, made this recommendation.
61
Task Force member, Dr. Molly Schwenn, Director, Maine Cancer Registry, made this recommendation.
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APPENDIX A
Authorizing Legislation, Resolves 2005, Chapter 121

CHAPTER121
H.P. 899- L.D. 1302
Resolve, Establishing The Task Force To Study Cervical Cancer Prevention, Detection and
Education
Emergency preamble. Whereas, acts and resolves of the Legislature do not become
effective until 90 days after adjournment unless enacted as emergencies; and
Whereas, this resolve establishes the Task Force to Study Cervical Cancer Prevention,
Detection and Education; and
Whereas, the study 1nust be initiated before the 90-day period expires in order that the study
may be completed and a report submitted in time for submission to the next legislative session;
and
Whereas, in the judgment of the Legislature, these facts create an emergency within the
meaning of the Constitution of Maine and require the following legislation as immediately
necessary for the preservation of the public peace, health and safety; now, therefore, be it
Sec. 1. Task force established. Resolved: That the Task Force to Study Cervical Cancer
Prevention, Detection and Education, referred to in this resolve as "the task force," is established;
and be it further
Sec. 2. Task force membership. Resolved: That the task force consists of the following 16
voting members:
1. Seven members appointed by the President of the Senate as follows:

A. One member of the Senate;
B. One representative of a women's health organization;
C. One communications consultant;
D. One representative of the American Academy of Pediatrics;
E. One representative of the American Academy of Family Physicians;
F. One licensed registered nurse; and
G. One representative of the Maine Medical Association or its successor;
2. Seven members appointed by the Speaker of the House of Representatives as follows:
A. Two members of the House of Representatives;
B. One representative of the American Cancer Society who is an oncologist;
C. One representative of the health insurance industry;
D. One representative of the American College of Obstetricians and Gynecologists;
E. One member of the Maine Osteopathic Association or its successor; and
F. One person who has survived cervical cancer;
3. The medical director of the Maine Cancer Registry or the medical director's designee; and
4. The Director of the Maine Breast and Cervical Health Program within the Department of
Health and Human Services, Bureau of Health and other members of the Bureau of Health, as
A-1

necessary to the work of the task force, who serve as ex officio nonvoting members of the task
force.
When making appointments to the task force, each appointing authority shall ensure that
appointees reflect the composition of the State's population with regard to ethnicity, race and
age; and be it further

Sec. 3. Chair. Resolved: That the Senate member shall serve as chair and the first-named
House member shall serve as vice-chair; and be it further
Sec. 4. Appointments; convening of task force. Resolved: That all appointments must be
made no later than 30 days after the effective date of this resolve. The appointing authorities
shall notify the Executive Director of the Legislative Council once all appointments have been
completed. The chair shall call and convene the first 1neeting of the task force by August 1,
2005; and be it further
Sec. 5. Quorum. Resolved: That a 1najority of the task force constitutes a quorum for the
transaction of its business; and be it further
Sec. 6. Committees. Resolved: That the task force chair may establish committees for the
purpose of making special studies pursuant to its duties and may appoint persons who are not
members of the task force to serve on each committee as resource persons. Resource persons are
voting members of the committees to which they are appointed. Committees may meet with the
frequency needed to accomplish the purposes of this resolve; and be it further
Sec. 7. Duties. Resolved: That the task force shall:
1. Review statistical and qualitative data on the prevalence and incidence of cervical cancer in
Maine;
2. Review preventive strategies and new technologies, including newly introduced vaccines
and their effectiveness in preventing and controlling the risk of cervical cancer, as well as their
relative costs;
3. Identify and examine the strengths and limitations of existing laws, regulations, programs
and services regarding coverage and awareness of cervical cancer;
4. Consider reports and testimony from individuals, local health departments, communitybased organizations, voluntary health organizations and other public and private organizations
statewide to learn more about their contributions to cervical cancer diagnosis, prevention and
treatment and their ideas for improving prevention, diagnosis and treatment in Maine;
5. Develop, in consultation with the Department of Health and Human Services, a statewide
comprehensive cervical cancer prevention plan and strategies for plan implementation and for
promoting the plan and awareness of the causes, risk factors, prevention, early detection and
treatment of cervical cancer to the general public, state and local elected officials and various
public and private organizations, associations, businesses, industries and agencies; and
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6. Recommend strategies for coordination and communication among state and local agencies
and organizations regarding their involvement in achieving the aims of the cervical cancer
prevention plan; and be it futiher
Sec. 8. Staff assistance. Resolved: That the Legislative Council shall provide necessary
staffing services to the task force; and be it further
Sec. 9. Compensation. Resolved: That legislative members of the task force are entitled to
receive the legislative per diem, as defined in the Maine Revised Statutes, Title 3, section 2, and
reimbursement for travel and other necessary expenses for their attendance at authorized
meetings of the task force. Public members not otherwise compensated by their employers or
other entities that they represent are entitled to receive reimbursement of necessary expenses and,
upon a demonstration of financial hardship, a per diem equal to the legislative per diem for their
attendance at authorized meetings of the task force; and be it further
Sec. 10. Report. Resolved: That, no later than December 7, 2005, the task force shall submit
an initial report to the Joint Standing Committee on Health and Human Services and the
Governor. The task force is not authorized to meet from December 21, 2005 to April25, 2006 or
to introduce legislation. The task force shall submit its final report to the joint standing
committee of the Legislature having jurisdiction over health and human services matters by
November 1, 2006. The joint standing committee of the Legislature having jurisdiction over
health and human services matters in the First Regular Session of the 123rd Legislature may
report out legislation on cervical cancer prevention, detection and education; and be it further
Sec. 11. Task force funding. Resolved: That the task force shall seek outside funds to fully
fund all costs of the task force. If sufficient outside funding has not been received by September
15, 2005 to fully fund all costs of the task force, no meetings are authorized and no expenses of
any kind may be incurred or reimbursed. Contributions to support the work of the task force may
not be accepted from any party having pecuniary or other vested interest in the outcome of the
matters being studied. Any person, other than a state agency, desiring to make a financial or inkind contribution must certify to the Legislative Council that it has no pecuniary or other vested
interest in the outcome of the study. Such certification must be made in the manner prescribed by
the Legislative Council. All contributions are subject to approval by the Legislative Council. All
funds accepted must be forwarded to the Executive Director of the Legislative Council along
with an accounting record that includes the amount of funds, the date the funds were received,
from whom the funds were received and the purpose of and any limitation on the use of those
funds. The Executive Director of the Legislative Council shall administer any funds received by
the task force. The executive director shall notify the chair of the task force when sufficient
funding has been received; and be it further
Sec. 12. Appropriations and allocations. Resolved: That the following appropriations and
allocations are made.
LEGISLATURE
Miscellaneous Studies 0444
Initiative: Provides an allocation of Other Special Revenue Funds in the event outside funding is collected to support
the activities of the Task Force to Study Cervical Cancer Prevention, Detection and Education. If sufficient outside
funding has not been received by September 15, 2005 to fully fund all costs of the task force, no meetings are
authorized and no expenses of any kind may be incurred or reimbursed.
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OTHER SPECIAL REVENUE
FUNDS
2005-06 2006-07

Personal Services $880
All Other
$3,600

$880
$3,600

OTHER SPECIAL REVENUE
FUNDS TOTAL $4,480 $4,480

Emergency clause. In view of the emergency cited in the preamble, this resolve takes effect
when approved.
Effective June 21, 2005.
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APPENDIXB
Task Force Membership List

Task Force to Study Cervical Cancer Prevention, Detection and
Education
Resolve 2005, Ch. 121
Appointment(s) by the President
Sen. Nancy B. Sullivan -Chair
20 Westwood Drive
Biddeford, ME 04005
207 282-5594
Kolawole Adewale Bankole M.D., M.S.
Amanda Lane, Lot #1 0
PO Box 5642
Ellsworth, ME 04605
Dina Cole BSN, RN, CPAN
9 Lemon Street
Veazie, ME 04401
Jonathan T. Fanburg M.D., M.P.H.
PO Box 1420
Ellsworth, ME 04605
Michael A. Jones M.D.
152 Morton Road
Yarmouth, ME 04096
Evelyn G. Kieltyka MSN, MS, FNP
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Janet Miles
PO Box 3205
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James Wilberg, M.D.
35 Stapleford Drive
Falmouth, ME 04105

Representing Cervical Cancer Survivors

Representing the American College of Obstetricians &
Gynecologists
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Dr. Molly Schwenn, Medical Director
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State House Station 11 4th Floor, Key Plaza
Augusta, ME 04333
207 287-8945
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Other
Sharon Jerome Program Director
MBCHP, Key Plaza, 4th Floor
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Augusta, ME 04333
207 287-6895

Director, Maine Breast & Cervical Health Program, DHHS
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APPENDIXC

Meeting Agendas

Task Force to Study Cervical Cancer Prevention,
Detection and Education
November 16, 2005, 1:00pm to 4:00pm
Room 427, State House

AGENDA
1:00pm

Welcome and Introductions

1:30pm

Overview of Task Force Legislation, Duties and Requirements

2:00pm

Where are we now? Overview of Cervical Cancer Incidence and Prevention,
Detection and Education Initiatives in Maine
•
•

3:00pm

Task Force Planning
•
•
•

4:00pm

Dr. Molly Schwenn, Director, Maine Cancer Registry
Sharon Gerome, Director, Maine Breast and Cervical Health Program

Establishing Priorities and Goals
Developing Work Plan I Schedule
Planning for Initial Report due December 2005

Adjournment

Next Meeting: December 16,2005 at 1:00pm in State House Room 427
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Task Force to Study Cervical Cancer Prevention,
Detection and Education
December 16, 2005, 1:00pm to 4:00pm
Room 427, State House

AGENDA
1:00pm

Introductions

1:15pm

Clinical Guidelines - Dr. Razcek

1:30pm

Technology Issues- Dr. Jones
• HPV/vaccine development
• Thin prep vs. conventional pap
• Women who are screened but for whom screening fails

2:00pm

MaineCare coverage of cervical cancer screening/treatment
Linda Schumacher and Maura Howard, DHHS

2:30pm

Western Maine Community Action Program, "At Your Cervix"
Nancy Audet, Program Manager, Tri-County Health Services

3:00pm

Report Back on the Cervical Cancer Summit, Rep. Marrache

3:15pm

Initial Report (Due December 23)- Staff review of outline I report drafting

4:00pm

Adjournment
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Task Force to Study Cervical Cancer Prevention,
Detection and Education
July 18, 2006, 1:OOpm to 4:00pm
Room 214, Cross Office Building

AGENDA
1:00pm

Introductions

1:15pm

Review and Updates
• Review of Initial Report
• Updates Recent News, Reports and Resources

1:45pm

Task Force Discussion/Work Session
• Remaining Duties and Schedule
• Developing a Statewide Cervical Cancer Prevention Plan- Next Steps

2:30pm

Break

2:45pm

Presentation I Maine Health Data Organization - Overview of Available Data
(Al Prysunka)

3:15pm

Presentation I Family Planning Association of Maine- Pap Test Data
(Evelyn Kieltyka)

3:45pm

Planning for Next Meeting

4:00pm

Adjournment

Next Meeting-- August 24, 2006, 9:30am-12:30pm
Cross Office
Room 214
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Task Force to Study Cervical Cancer Prevention,
Detection and Education
August 24, 2006, 9:30am-12:30pm
Room 214, Cross Office Building

AGENDA
9:30am

Introductions

9:45am

Merck I Gardasil

10:30am

Maine Immunization Program
Sally Lou Patterson, Director, Division of Infectious Disease, DHHS

ll:OOam

Family Planning Association I Pap Test Data
Evelyn Kieltyka, Senior Vice President ofProgram Services

11:30am

Task Force Discussion & Work Session

12:15pm

Planning for Next Meeting

12:30pm

Adjournment

Next Meeting- September 19, 2006, 1:30am-4:30pm
Cross Office Building, Room 214

------------------------~
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Task Force to Study Cervical Cancer Prevention,
Detection and Education
September 26, 2006, 1 :30-4 :30pm
Room 214, Cross Office Building

AGENDA
1:30pm

Introductions

1:45pm

Task Force Work Session- Development of Recommendations

4:15pm

Planning for Next Meeting

4:30pm

Adjournment

Meeting - October 17, 2006, 1 :30-4 :30pm
Cross Office
Room 214
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Task Force to Study Cervical Cancer Prevention,
Detection and Education
October 17, 2006, 1 :30-4:30pm
Room 214, Cross Office Building

AGENDA
1:30pm

Introductions

1:45pm

Task Force Work Session -Review of Draft Report

4:30pm

Adjournment
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APPENDIXD
Draft Legislation to Implement Task Force Recommendations

An Act to Implement the Recommendations of the Task Force to Study Cervical
Cancer Prevention, Detection and Education

Be it enacted by the People of the State of Maine as follows:
Part A
Sec A-1. State funding for the human papillomavirus vaccine. Beginning with
state fiscal year 2006-07, the Maine Legislature shall provide funding to the Maine
Immunization Program to support the purchase and distribution of the human
papillomavin1s vaccine and associated program operation costs. The Legislature shall
appropriate the funds necessary to provide the human papillomavirus vaccine to all 11
and 12 year old females in the state after utilizing all available federal funding and
federally-purchased vaccine.

Sec. A-2. Maine Immunization Program to report on program funding and
vaccination rates. The Maine Immunization Program shall report to the joint standing
committee of the Legislature having jurisdiction over health and human services matters
regarding the status of program funding and vaccination rates. The program shall submit
an initial report to the committee no later than January 30, 2008, and a second report no
later than January 30, 2010. Each report must include the following:
1. Program budget information for the current year and previous two years,
including specific information regarding expenditures on the human papillomavirus
vaccine;

2. Documentation of any funding shortage that exists between available funds
and the expenditures required to vaccinate 80o/o of Maine children with the human
papillomavirus vaccine and the other vaccines on the federal Centers for Disease Control
and Prevention recommended childhood and adolescent vaccine schedule; and
3. State and national immunization rates for the human papillomavirus vaccine
and the other vaccines on the federal Centers for Disease Control and Prevention
recommended childhood and adolescent vaccine schedule.

Sec. A-3. MaineCare coverage of the human papillomavirus vaccine. The
Department of Health and Human Services shall amend the rules for the MaineCare
program to provide coverage for the human papillomavirus vaccine in accordance with
the federal Centers for Disease Control and Prevention's current recommended childhood
and adolescent immunization schedule and current recommended adult immunization
schedule as published in the Morbidity and Mortality Weekly Report. The Office of
MaineCare Services shall provide information regarding human papillomavirus
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vaccination among MaineCare members to the Maine Center for Disease Control and
Prevention for inclusion in the initial and final evaluation reports required under Section
D-3.

PartB
Sec. B-1. Statewide public education campaign regarding cervical cancer.
The Maine Breast and Cervical Health Program, referred to in this section as "the
program," shall develop and implement a statewide public education campaign regarding
cervical cancer prevention and early detection, including the importance of cervical
cancer screening and the availability of the human papillomavirus vaccine. In carrying
out the campaign, the program shall:
1. Broadcast public service announcements, including information about cervical
cancer prevention and early detection, for all 12 months of the year;

2. Distribute printed information materials regarding cervical cancer to all sites
that currently receive program brochures and to additional locations statewide including,
but not litnited to, libraries, shopping malls, grocery stores, hair salons and health care
facilities. The program must also offer these informational materials to faith-based
organizations;
3. Collaborate with the Office of Minority Health to develop specific outreach
initiatives for racial and ethnic minority populations in the state. Informational materials
developed pursuant to subsection 2 must be translated into languages other than English,
as appropriate; and
4. Consult with state and local organizations representing senior citizens and
retired person to develop specific outreach initiatives to reach women over 60 years.
The program shall report its progress and results in implementing this section to the
Maine Center for Disease Control and Prevention for inclusion in the initial and final
evaluation reports required under Section D-3.

Sec. B-2. School-based cervical cancer education initiatives. The Maine Center
for Disease Control and Prevention, referred to in this section as "the center," shall
coordinate the development and implementation of school-based cervical cancer
education initiatives in accordance with this section.
1. The center shall develop printed materials on cervical cancer prevention and

early detection appropriate for students in grades 6-12 and college students to be posted
at schools and universities. The center shall collaborate with the Maine Department of
Education and the University of Maine System to coordinate the distribution and posting
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of materials at public schools and universities. The center shall offer these materials to
private schools and colleges;
2. The center shall develop an educational pamphlet regarding the HPV vaccine
for students in the fifth grade. The center shall collaborate with health education staff
within the Department of Education, school nurses and health coordinators to facilitate
the distribution of the pamphlet in public schools. The center shall provide copies of the
pamphlet to all pediatricians and family physicians licensed in the state and shall offer the
pamphlet to private schools;
3. The center shall collaborate with health education staff of the Department of
Education to develop a listing of medical professionals willing to speak about cervical
cancer prevention in health education classes or other appropriate forums in public
schools on a voluntary basis; and
4. The center shall seek grant funding to implement an activity-based cervical
cancer educational initiative in schools. The center shall seek input from the Department
of Education in developing its proposal and applying for grant funding.
The center shall report its progress and results in implementing this section in the initial
and final evaluation reports required under section D-3.

Sec. B-3. Continuing medical education regarding cervical cancer. The Maine
Center for Disease Control and Prevention shall collaborate with the Maine Medical
Association's Committee on Continuing Medical Education and Accreditation to identify
and implement strategies to expand continuing medical education opportunities regarding
cervical cancer, including but not limited to: current clinical guidelines for cervical
cancer screening; human papillomavirus vaccines; and emerging issues and technologies
in cervical cancer prevention, detection and treatment. The Maine Center for Disease
Control and Prevention shall encourage the Maine Medical Association to conduct
outreach efforts to promote cervical cancer continuing education offerings to its members
and inform them of the current status of the human papillomavirus vaccines, including
availability, cost and insurance coverage. The Maine Center for Disease Control and
Prevention shall report its progress and results in implementing this section in the initial
and final evaluation reports required under section D-3.

Parte
Sec C-1. Medicaid waiver for family planning services. The Department of
Health and Human Services, including representatives of the Office of MaineCare
Services and the Maine Breast and Cervical Health Program, in consultation with the
Family Planning Association of Maine, Inc., shall examine the potential costs and
benefits of obtaining a state Medicaid family planning waiver to provide cervical cancer
screening and related services to individuals who do not otherwise qualify for the state
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MaineCare program. The examination must include an assessment of the potential value
of such a waiver to the state's efforts to cervical cancer prevention and early detection.
No later than January 1, 2008, the department shall make a recommendation to the joint
standing committee of the Legislature having jurisdiction over health and human services
matters regarding whether the state should apply to the federal Department of Health and
Human Services, Centers for Medicare and Medicaid Services for a waiver.

Sec. C-2. Maine Breast and Cervical Health Program eligibility expansion.
The Department of Health and Human Services shall amend the rules regarding eligibility
for the Maine Breast and Cervical Health Program to grant eligibility for cervical cancer
screening and related services to women ages 35 to 39 years who meet all other eligibility
criteria for the program. The program shall report its experience under this rule change to
the Maine Center for Disease Control and Prevention for inclusion in the initial and final
evaluation reports required under section D-3.

Sec. C-3. Maine Breast and Cervical Health Program screening initiatives.
The Maine Breast and Cervical Health Program shall implement the following initiatives
to increase and improve cervical cancer screening:
1. The program shall collaborate with the Family Planning Association of Maine,

Inc., to develop ideas for outreach and coordination to increase cervical cancer screening
among women who are ineligible for the program, with particular attention to women
under 35 years of age;
2. The program shall expand its special screening days. The expansion may
include adding more sites, adding more screening days at current sites or a combination
of these strategies, based on the program's assessed need and demand for services;
3. The program shall update its clinical guidelines for cervical cancer screening,
based on a review of the most recent clinical guidelines for cervical cancer screening
published by the American Cancer Society, the American College of Obstetricians and
Gynecologists and the United States Preventive Services Task Force. The program shall
offer a professional education program on clinical guidelines for cervical cancer
screening after it has completed the update; and
4. The program shall coordinate a stakeholder group including representatives of
the Maine Comprehensive Cancer Control Program, the State Employee Health
Commission, the American Cancer Society, and health insurance carriers operating in the
State to explore options for encouraging insured individuals to make and attend medical
appointments for cancer screening including, but not limited to, cervical cancer
screening.
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The program shall report its progress and results in implementing this section to the
Maine Center for Disease Control and Prevention for inclusion in the initial and final
evaluation reports required under section D-3.

Sec. C-5. Maine Quality Forum review and report on health care system
initiatives affecting the delivery of cervical cancer screening services. The Maine
Quality Forum shall identify and assess current initiatives within the state health care
system that may enhance the delivery of cervical cancer screening and follow-up medical
care, including computer-based clinical improvement systems to track and manage
patient care, provider incentives and health care quality and performance measures. The
forum shall report its findings, and any recommendations, to the Maine Center for
Disease Control and Prevention for inclusion in the initial evaluation report required
under section D-3.

PartD
Sec. D-1. Cervical cancer incidence and prevention in racial and ethnic
minority populations. The Office of Minority Health shall, in collaboration with the
Maine Cancer Registry, the Office of Multicultural Affairs and the Maine Comprehensive
Cancer Control Program, examine cervical cancer incidence in racial and ethnic minority
populations in the State and develop recommendations to improve cervical cancer
prevention and early detection in these populations. The project must consider:
1. Available data on cervical cancer incidence among racial and ethnic

minorities;
2. Barriers to cervical cancer screening and treatment across different racial and
ethnic minorities; and
3. Best practices in public health education and outreach to racial and ethnic
minorities.
The Office of Minority Health shall report its findings and recommendations to the
Maine Center for Disease Control and Prevention for inclusion in the initial evaluation
report required under section D-3.
Sec. D-2. Geographic variations in cervical cancer rates. The Maine Cancer
Registry shall, in collaboration with the Maine Breast and Cervical Health Program,
examine geographic variation in cervical cancer rates within the state, with particular
attention to the higher rates of cervical cancer observed in Washington County and
Somerset County, and shall explore reasons for the variation. The Maine Cancer
Registry and the Maine Breast and Cervical Health Program shall consult with the
American Cancer Society, community organizations and health care providers to develop
recommendations for reducing the incidence of cervical cancer in Washington County
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and Somerset County. The Maine Cancer Registry shall report its findings and
recommendations to the Maine Center for Disease Control and Prevention for inclusion
in the initial evaluation report required under section D-3.

Sec. D-3. Evaluation of cervical cancer prevention, detection and education
initiatives. The Maine Center for Disease Control and Prevention shall monitor and
evaluate the State's progress in cervical cancer prevention, detection and education in
response to the work of the Legislature's Task Force to Study Cervical Cancer
Prevention, Detection and Education. The center shall submit two evaluation reports to
the joint standing committee of the Legislature having jurisdiction over health and human
services matters. The reports must address the progress, status and outcomes of each
recommendation contained in the final report of the Task Force including, but not limited
to, each initiative required under this Act. The initial evaluation report must be submitted
no later than January 30, 2009, and the final evaluation report must be submitted no later
than January 30, 2011. After review of the initial report, the joint standing committee of
the Legislature having jurisdiction over health and human services matters may report out
legislation regarding cervical cancer prevention, detection and education to the First
Regular Session of the 124th Legislature. After review of the final report, the joint
standing committee of the Legislature having jurisdiction over health and human services
matters may report out legislation regarding cervical cancer prevention, detection and
education to the First Regular Session of the 125th Legislature.

SUMMARY

This bill implements the recommendations of the Task Force to Study Cervical
Cancer Prevention, Detection and Education.
Part A of the bill relates to the human papillomavirus vaccine. It specifically does
the following:
1. It requires the Maine Legislature to provide funding to the Maine
Immunization Program for purchasing and distributing the human papillomavirus vaccine
to all 11 and 12 year old females.
2. It requires the Maine Immunization Program to report to the joint standing
committee of the Legislature having jurisdiction over health and human matters on the
status of program funding and vaccination rates, including specific information on the
human papillomavirus vaccine, by January 30, 2008 and again by January 30, 2010.
3. It requires the Department of Health and Human Services to amend the rules
for the MaineCare program to include coverage for the vaccine.
Part B of the bill relates to improving public awareness and education
regarding cervical cancer prevention. It specifically does the following:
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1. It requires the Maine Breast and Cervical Health Program to develop public
education materials regarding cervical cancer prevention and the human papillomavirus
vaccine to be distributed to sites that currently receive the program's materials, as well as
locations that include libraries, malls, health care facilities and others. It requires the
materials to be translated into languages other than English when necessary.
2. It requires the Maine Center for Disease Control and Prevention to coordinate
with the Maine Department of Education and the University of Maine System to develop
educational materials for schools and universities, including a 5th grade pamphlet. In
addition, the Center must develop a voluntary speakers group for health and other classes.
3. It requires the Maine Center for Disease Control and Prevention to collaborate
with the Maine Medical Association to develop and expand continuing medical education
units related to cervical cancer, including appropriate screening guidelines and
vaccination materials.
Part C of the bill relates to expanding cervical cancer screening opportunities.
It specifically requires the following:

1. It requires the Department of Health and Human Services to consult with
MaineCare, the Maine Breast and Cervical Health Program, and the Family Planning
Association of Maine to determine the potential costs and benefits of obtaining a federal
Medicaid family planning waiver to provide cervical cancer screening and related
services to individuals that do not currently qualify for MaineCare.
2. It requires the Maine Breast and Cervical Health Program to expand eligibility
to include women ages 35-39 years who meet all other eligibility criteria for the program.
3. It requires the Maine Breast and Cervical Health Program to: coordinate with
the Family Planning Association of Maine to increase cervical cancer screening among
women under 35 years of ages; expand screening days to new sites or additional days;
update screening guidelines; and work with the Maine Comprehensive Cancer Control
Program, the State Employee Health Commission, the American Cancer Society, and
health insurance carriers to explore options for encouraging people to attend cancer
screenings.
4. It requires the Maine Quality Forum to identify and assess current initiatives
within the state health care system that may enhance delivery of cervical cancer screening
and follow-up care.
Part D relates to future research in cervical cancer. It specifically does the
following:
1. It requires the Office of Minority Health to collaborate with the Maine Cancer
Registry, the Office of Multicultural Affairs, and the Maine Comprehensive Cancer

D-7

Control Program to examine cervical cancer incidence in racial and ethnic minorities in
the state and study barriers to screening and treatment and best practices for overcoming
those barriers.
2. It requires the Maine Cancer Registry to collaborate with the Maine Breast
and Cervical Health Program to examine the higher incidence of cervical cancer in
Washington County and Somerset County to determine reasons for the variation and
develop recommendations for reducing cervical cancer in those counties.
3. It requires the Maine Center for Disease Control and Prevention to monitor
and evaluate state progress in implementing the Task Force recommendations and report
to the joint standing committee of the Legislature having jurisdiction over health and
human services by January 30, 2009, and again by January 30, 2011.
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APPENDIXE
Excerpts from Maine Cancer Plan 2006-2010

SEXUAL HEALTH
Certain sexually transmitted diseases, including human papillomavirus (1-iPV), hepatitis B (HBV),
and human imrnunodeficiency virus (HIV)I are associated with cancer. Certain types of HPVI
specillcally HPV-16 and f-IPV-18, are the major cat!ses of cervical cancer and may also p!ay a role in
cancers of the anus, vulva,

and penis. Hepatitis viruses/ particularly H BV, have been linked

to liver cancers, and HIV has been linked with lymphoma, anal cancel~ and Kaposi's sarcoma. Risk
factors for sexually transmitted diseases (STDs) inchtde unprotected sexual contact and multiple
partners.
Currently, early detection of certain HPV types, such as HPV-16 and -18 is the standard for
prevention of cervical cancer. However, with new technologies emerging for HPV-testing, the
development of effective HPV vaccines, and increased awareness of HPV among the general public,
there may be more emphasis on primary prevention of cervical cancer. AdditionaiiYr methods used
to prevent other STDs will have some impact on reducing the incidence of HPV infection and,
indirectly, the incidence of cervical cancer.

Objective 1: Reduce by 10% the incidence of sexually transmitted diseases
associated with the develop1nent of cancer in Maine by 2010.
Baseline: 12 cases of Acute HBV incidence in Maine, J\!1aine CDC STD Program, 2004 1 National
HPV incidence estimate: 6.2 million.
Strategies
1. Provide health care/social service professionals w1th at least llve opportunities for l-IPV

education.
2. Promote public knowledge about HPV by developing and disseminating at least 500 fact

sheets for females and health care professionals through collaboration between the Maine
Breast and Cervical Health Program, the J\!laine Comprehensive Cancer Program and the
J\11aine HIV, STD and Viral Hepatitis Program.

3. Increase the number of HIV and STD prevention interventions that target individuzds at high
risk for HPV, HBV and HJV infection.
4. Conduct at least two public education campaigns to promote safer sex and/or vaccines by 2010.
5. Seek funding for HPV vaccination.

38

Objective 2: Promote Hepatitis B vaccine for Maine children 19-35 rnonths of age.
Baseline: 92% received 3 or more doses of hepatitis 13 vaccine, CDC National Immunization Survey,
2004_

Objective 3: Promote Hepatitis B vaccines for at-risk adults accessing STD clinics.
Strategies
1_Implement at least two interventions annua11y to increase the number of children who receive

Hepatitis B vaccine by the time they enter kindergarten.
2. Provide at least two opportunities annually for people working with middle school children

to learn more about viral hepatitis prevention and resources_

3_ Increase the proportion of sexually active adults who receive free Hepatitis B vaccine by 2010_

Objective 4: Increase abstinence to 60%

a~nong

sexually active 9- 12th graders by

2010
Baseline: 55%, MYRBS, 2005.

Objective 5: Increase condotn use at last intercourse to 63% an1ong sexually active
9- 12th graders by 2010.
Baseline: 59%, MYRBS, 2005.

Strategies
1. Implement Comprehensive School Health Education and a Coordinated School I---lealth

Program that includes an age appropriate comprehensive sex education curriculum.
2. Provide sexuality counseling c1nd education.

3. Provide condoms and full family planning services through high school health center
grantees.
4. Conduct public education to promote condom use as a social/community norm.

5. Seek funding to support and expand efforts.

ENVIRONMENTAL HEALTH
About 20 chemicals found in the environment, including arsenic, asbestos, benzene, cadmium,
chromium, radon, and vinyl chloride, have been identified as known human carcinogens by national
and international agencies. J\1any additional chemicals have been identified as being potential
human carcinogens. The cancer burden posed by specific environmental carcinogens (aside
from occupational exposure) has not been well defined. Despite the fact that the contribution of
environmental carcinogens to the cancer burden is not as well understood as some of the other
major causes of cancer, such as tobacco use, preventive measures should be initiated. Such measures
are largely based on what is known at the present and include the reduction of exposure to
hazardous chemicals in the workplace and the reduction of environmental pollution.
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CERVICAL CANCER
Cervical cancer screening is important to detect signifkant abnormal cell changes that may arise
before cancer develops. Since the introduction of the Papanicolaou (Pap) test, cervical cancer
incidence and mortality rates have significantly declined in the United States and in !Vlaine (Figures
22 & 23). Less than fifty women in J\1aine were diagnosed with cervical cancer in 2005. While the

number of women affected by cervical cancer is relatively small compared to other cancers, it is one
of the most preventable and treatable cancers. 60

Cervical Cancer:

Age~Adjusted
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22:

A!Je-Adj1ASted Cervical Cancer Incidence Rates, 1995-2002
Results Pro_qram and the Maine Cancer Registry Program.

Source: Sumei1lancc, Et>idemiology and

Cervical Cancer: Age-Adjusted Mortality Rates, 1995-2002

Figure

A!Je-Adjusted
Cancer lV1ortality Rates,
SmArcc: National Center for f-lealtf; Stotistics
23:

1995-2002
Sl

The primary risk factor for cervical cancer is certain types of human papillornavirus (!·-! PV) Other
risk factors include smoking, poor nutrition, and immunosuppression. 61 Southeast Asian women have
the highest invasive cervical cancer incidence rates. For example, cervical cancer incidence rates are
five times higher among Vietnamese American women than white women 62
Additionally, after the age of 25, the incidence and mortality of invasive cancer in African American
women increases rapidly with age, while in white women, it rises more slowly.
Studies have shown repeatedly that early detection is effective in reducing the number of women
dying of cervical cancer. With routine screening, women significantly improve their odds of
finding cervical cancer at its earliest and most treatable stages. Several national organizations have
developed screening guidelines (Appendix D).
In 2004, almost 89% of Maine women had a Pap test within three years. This is one of the
highest screening rates for cervical cancer in United States. This is due in part to the successful
implementation of the Maine Breast and Cervical Health Program, which offers free mammography
and Pap tests to income eligible women ages 40 and over. Advocacy and education efforts have also
played an important role. Additionally, al1Iv1aine insurers are required to pay for cervical cancer
screening, which helps to reduce the financial barrier to getting screened.

Baseline: 2.1 per 100,000 death\ 1V1aine Cancer Registry, 2002.

Objective 1: Increase the proportion of Maine women with a uterine cervix who
have ever received a Pap test to 98% by 2010.
Baseline: 96(){} of women aged 18 and older with a uterine cervix have ever received a Pap test,

BRFSS, 2004.
Strategies
1. Provide advocacy for ongoing implementation of !Ylaine Breast and Cervical Health

Program.
2. Provide advocacy for ongoing funding of Title X (family Planning) activities.

3. Provide continuing education programs about cervical cancer screening inclusive of HPV
and vaccine education to health care professionals.
4. Collaborate with organizations that represent women with a higher prevalence of cervical

cancer to develop and disseminate culturally and linguistically appropriate messages
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Objective 2: Increase the proportion of Maine women with a uterine cervix that
received a Pap test within the preceding 1 to 3 years to 92% by 2010.
Baseline: 899'<> of women aged 18 and older with a uterine cervix have received a Pap test within the
previous 3 years, BRFSS, 2004.
Strategies
1. Provide advocacy for ongoing implementation of Maine Breast and Cervical Health

Program
2. Provide advocacy for ongoing funding of Title X (Family Planning) activities.
3. Provide continuing education programs about cervical cancer screening inclusive of

HPV

and vaccine education to health care professionals.
4. Collaborate with organizations that represent women with a higher prevalence of cervical

cancer to develop and disseminate culturally and linguistically appropriate messages.

Objective 3: Maintain the proportion olpatients diagnosed with invasive cervical
cancer who receive or have access to appropriate treatment (within 60 days to
treatn1ent starting) by 2010.
Baseline: 100% Maine Breast and Cervical Health Program/April 2005 MDE Submission Data
Quality.
Strategies

l. Develop a relationship with cancer treating hospitals to explore the collection of
data on timely results.

Objective 4: Reduce the number of women who are diagnosed with regional or
distant stage cervical cancer by 2010.
Baseline: 30% Regional and 6(XJ Distant, Maine Cancer Registry, DHHS, 1995-2002.
Strategies
I. Conduct case studies of current cancer deaths.
2. Develop interventions based on the analysis of case studies.
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